PubMed
NAD+ metabolism and its roles in cellular processes during ageing
Covarrubias AJ, Perrone R, Grozio A, et al. Nat Rev Mol Cell Biol. 2021
Compare
NAD+ vs VIP
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
NAD+
96 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 2% · Mixed 98% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Energy
197
Appetite
197
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Headache
66
Nausea
64
Injection site irritation
64
Self-reported dose per injection
Median bucket: 5+ mg · Most common: 5+ mg
Reports span 0.1 to ≥ 5 mg (open-ended top bucket)
0.1–0.2 mg
2
0.2–0.4 mg
17
0.4–0.6 mg
8
0.6–1 mg
1
1–2 mg
2
3–5 mg
2
5+ mg
165
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 95% said they felt similar to their last entry, 5% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 51 days · Based on 42 repeat reporters
VIP
25 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 2% · Mixed 2% · Unfavorable overall 96%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
163
Energy
6
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Nausea
83
Headache
77
Self-reported dose per injection
Median bucket: 50–100 mcg · Most common: 50–100 mcg
Reports span 50–200 mcg
50–100
116
100–200
47
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 88% said they felt similar to their last entry, 13% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 152 days · Based on 24 repeat reporters
Sources (17)
Published sources linked on the NAD+ and VIP wiki pages.
- Wiki study page →Source
- Wiki study page →Source
PubMed
Safety and efficacy of NAD+ supplementation: a systematic review
Reiten OK, Wilvang MA, Mitchell SJ, et al. J Clin Invest. 2021
- Wiki study page →Source
PubMed
NAD+ intermediates: The biology and therapeutic potential
Yoshino J, Baur JA, Imai SI. Cell Metab. 2018
- Wiki study page →Source
ClinicalTrials.gov
NAD+ studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Nicotinamide Adenine Dinucleotide in Aging Biology: Potential Applications and Many Unknowns
Bhasin S, Seals D, Migaud M, et al. Endocrine reviews. 2023
- Wiki study page →Source
PubMed
NAD⁺ in aging, metabolism, and neurodegeneration
Verdin E. Science (New York, N.Y.). 2015
- Wiki study page →Source
PubMed
NAD+ and sirtuins in aging and disease
Imai S, Guarente L. Trends in cell biology. 2014
- Wiki study page →Source
PubMed
The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update
Song Q, Zhou X, Xu K, et al. Advances in nutrition (Bethesda, Md.). 2023
- Wiki study page →Source
PubMed
Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension
Ghatei MA, Takahashi K, Suzuki H, et al. J Cardiovasc Pharmacol. 2003
- Wiki study page →Source
PubMed
Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo
Delgado M, Chorny A, Gonzalez-Rey E, et al. J Leukoc Biol. 2005
- Wiki study page →Source
PubMed
Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions
Delgado M, Ganea D. Amino Acids. 2013
- Wiki study page →Source
PubMed
Vasoactive intestinal peptide: cardiovascular effects
Henning RJ, Sawmiller DR. Cardiovascular Research. 2001
- Wiki study page →Source
PubMed
Vasoactive intestinal peptide and the mammalian circadian system
Vosko AM, Schroeder A, Loh DH, et al. General and Comparative Endocrinology. 2007
- Wiki study page →Source
PubMed
New perspectives on vasoactive intestinal polypeptide as a widespread modulator of social behavior
Kingsbury MA. Current Opinion in Behavioral Sciences. 2015
- Wiki study page →Source
ClinicalTrials.gov
Vasoactive Intestinal Peptide studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
The significance of vasoactive intestinal peptide in immunomodulation
Delgado M, Pozo D, Ganea D. Pharmacological reviews. 2004
- Wiki study page →Source
PubMed
Role of vasoactive intestinal peptide in osteoarthritis
Jiang W, Wang H, Li YS, et al. Journal of biomedical science. 2016